IP Library Granted Patent US 11,104,915
Granted Patent B2
US 11,104,915 · App. 15/754,598 · Granted Aug 31, 2021

Viral vector assay and vector

Inventors: Nigel Parker (Chinnor, GB); Hanna P. Lesch (Kuopio, FI); Jenni Mykkanen (Kuopio, FI); Sara Paulo (Kuopio, FI); Minna Hassinen (Kuopio, FI); Robert Shaw (Kuopio, FI)
Assignee: Trizell Ltd.
C12N15/86G01N33/56983C12N2710/10343C12N2710/10351
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,104,915
App. No.
15/754,598
Granted
Aug 31, 2021
Kind
B2
Abstract

A process for assaying viral vector manufactured by large-scale viral vector manufacturing processes to assure the resulting vector has acceptable purity and potency. The process entails three different types of assays, each one of which is optionally useful on a stand-alone basis, and which together provide the first system able to assure the quality of viral vector produced by large-scale vector manufacturing processes.

Claims (8)

1. A process for manufacturing a viral vector having an expressible transgene that can express a polypeptide that has biological activity, comprising: obtaining a sample of the viral vector having the expressible transgene that can express the polypeptide that has biological activity, and then

assaying said sample by a. measuring viral vector infectious titer by calculating a linear response curve to measure relative infectivity using the Slope Ratio method; and using at least two assays selected from the group consisting of:

b. measuring transgene expression,

c. measuring the activity of the polypeptide expressed by said transgene, and

d. measuring viral particle titer.

2. The process of claim 1 , wherein said assaying said sample comprises a. measuring viral vector infectious titer by calculating a linear response curve to measure relative infectivity using the Slope Ratio method, b. measuring transgene expression and c. measuring the activity of the polypeptide expressed by said transgene.

3. The process of claim 1 , wherein said assaying said sample comprises d. measuring viral particle titer.

4. The process of claim 1 , wherein said assaying said sample comprises: a. measuring viral vector infectious titer, b. measuring transgene expression, c. measuring the activity of the polypeptide expressed by said transgene, and d. measuring viral particle titer.

Assignments (5)
CHANGE OF NAME Recorded Jul 10, 2025
From: TRIZELL LTD
To: FERRING VENTURES LTD
Reel/Frame 071655/0966 →
RELEASE OF SECURITY INTEREST Recorded Jan 31, 2022
From: PHARMACEUTICAL PATENT ATTORNEYS, LLC
To: TRIZELL LTD., F/K/A FINVECTOR LTD. F/K/A ARK THERAPEUTICS LTD.
Reel/Frame 058826/0044 →
SECURITY INTEREST Recorded Nov 19, 2020
From: TRIZELL LTD.
To: PHARMACEUTICAL PATENT ATTORNEYS, LLC
Reel/Frame 054775/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2018
From: PARKER, NIGEL; LESCH, HANNA P; MYKKANEN, JENNI; PAULO, SARA; HASSINEN, MINNA; SHAW, ROBERT
To: FINVECTOR VISION THERAPIES LTD.
Reel/Frame 045031/0322 →
CHANGE OF NAME Recorded Feb 26, 2018
From: FINVECTOR VISION THERAPIES LTD.
To: TRIZELL LTD.
Reel/Frame 045031/0343 →
Continuity (2)
Provisional Application 62218810 · Sep 15, 2015
Related Publication 20190338307A1 · Nov 7, 2019